IgA Nephropathy Clinical Trials

176 clinical trials for IgA Nephropathy across international registries, including 43 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN — RECRUITING · PHASE3
• Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases — RECRUITING · PHASE2
• A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G — RECRUITING · PHASE2
• A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases. — RECRUITING · PHASE1
• Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease — RECRUITING · PHASE2
• A Study of JADE101 in Participants With Immunoglobulin A Nephropathy — RECRUITING · PHASE2
• Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis — RECRUITING
• RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN) — RECRUITING
• Study of BHV-1400 in IgA Nephropathy — RECRUITING · PHASE1
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept — RECRUITING · PHASE2
• Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study — RECRUITING · PHASE2
• A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy — RECRUITING · PHASE2
• Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN — RECRUITING · PHASE3
• CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease — RECRUITING · PHASE1
• IgA Nephropathy Biomarkers Evaluation Study (INTEREST) — RECRUITING
• Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease — RECRUITING · PHASE1
• Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy — RECRUITING · PHASE4
• CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease — RECRUITING · PHASE1
• A MULTICENTER OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ZIGAKIBART IN ADULTS WITH PRIMARY IGA NEPHROPATHY — RECRUITING
• A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy — RECRUITING
• A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy — RECRUITING · PHASE2
• A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE EFFICACY AND SAFETY OF MEZAGITAMAB (TAK-079) IN STUDY PARTICIPANTS WITH PRIMARY IGA NEPHROPATHY IN COMBINATION WITH STABLE BACKGROUND THERAPY — RECRUITING · PHASE3
• Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN) — RECRUITING · PHASE2
• Nefecon and Ambrisentan in IgA Nephropathy — RECRUITING · PHASE4
• Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy? — RECRUITING · PHASE4
• Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial — RECRUITING · NA
• Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue — RECRUITING · PHASE2
• Correlation of Microbiome and Metabonomics With IgA Nephropathy — RECRUITING
• A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria — RECRUITING · PHASE3
• Raman Spectroscopy Diagnosis of Kidney Diseases — RECRUITING
• Efficacy and Safety of Telitacicept in IgAN — RECRUITING · NA
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF FELZARTAMAB IN ADULTS WITH IGA NEPHROPATHY — RECRUITING · PHASE3
• Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy — RECRUITING · PHASE2
• A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects — RECRUITING · PHASE1
• National Registry of Rare Kidney Diseases — RECRUITING
• A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SEFAXERSEN, AN ANTISENSE INHIBITOR OF COMPLEMENT FACTOR B, IN PATIENTS WITH PRIMARY IGA NEPHROPATHY AT HIGH RISK OF PROGRESSION — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BION-1301 IN ADULTS WITH IGA NEPHROPATHY (THE BEYOND STUDY) — RECRUITING · PHASE3
• A PHASE IIB RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATACICEPT IN SUBJECTS WITH IGA NEPHROPATHY (IGAN) — RECRUITING · PHASE2
• A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER PHASE IIA, CLINICAL TRIAL TO ASSESS EFFICACY AND SAFETY OF THE HUMAN ANTI-CD38 ANTIBODY FELZARTAMAB IN IGA NEPHROPATHY - IGNAZ — RECRUITING · PHASE2
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY AT RISK OF PROGRESSIVE LOSS OF RENAL FUNCTION (THE ALIGN STUDY) — RECRUITING · PHASE3
• IgA Nephropathy Registration Initiative of High Quality (INSIGHT) — RECRUITING
• KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis — RECRUITING
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF NEFECON IN PATIENTS WITH PRIMARY IGA NEPHROPATHY AT RISK OF PROGRESSING TO END-STAGE RENAL DISEASE (NEFIGARD) — RECRUITING
• An open-label, uncontrolled, multicenter study to assess the effect of zigakibart treatment on histologic, circulating, and excreted markers of kidney disease and dysfunction in adult patients with IgA nephropathy — TERMINATED · PHASE2
• A Study of Treatment Patterns and Real-World Outcomes in IgA Nephropathy Patients in the United States — COMPLETED
• Universal STAR-T Cell Injection in Autoimmune Kidney Diseases — NOT_YET_RECRUITING · NA
• Serum and Urinary sCD163 in IgA Nephropathy — ACTIVE_NOT_RECRUITING
• A multicenter open-label extension study to evaluate the long-term safety and tolerability of zigakibart in adults with primary IgA nephropathy — NOT_YET_RECRUITING · PHASE3
• Autoimmune Protocol Diet Intervention on Proteinuria in IgA Nephropathy Patients — WITHDRAWN · NA
• Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy — COMPLETED · PHASE2

Refine this search